Evidence map›Paper›PMID 26712744›Full record

ReviewInternational journal of molecular sciences2015

RUCAM in Drug and Herb Induced Liver Injury: The Update.

Gaby Danan, Rolf Teschke

Registry-linked trialAbstract readComparative StudyReview
In one paragraph

Review in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04964310 (Pharmacogenomics of APAP Induced DILI in Chinese Population.), which is not on this map. Cited by 432 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
432citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04964310 recruitingnot on this mapstarted 2020, after this paper: background citation

Pharmacogenomics of APAP Induced DILI in Chinese Population.

TypeobservationalSponsorThe First Affiliated Hospital with Nanjing Medical UniversityRan2020 to 2026Enrolled339ConditionsAcetaminophen, Drug-Induced Liver Injury, Pharmacogenetics, ChinaArmsgenetic polymorphism
3 · Its place in the literature

Who cites it

432 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. [Chinese guideline for diagnosis and management of drug-induced liver injury (2023 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023
    Guideline
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

372 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Gaby DananPharmacovigilance Consultancy, rue des Ormeaux, 75020 Paris, France. gaby.danan@gmail.com.
Rolf TeschkeDepartment of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, Academic Teaching Hospital of the Medical Faculty, Goethe University Frankfurt/Main, Frankfurt am Main, D-63450 Hanau, Germany. rolf.teschke@gmx.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RUCAM (Roussel Uclaf Causality Assessment Method) or its previous synonym CIOMS (Council for International Organizations of Medical Sciences) is a well established tool in common use to quantitatively assess causality in cases of suspected drug induced liver injury (DILI) and herb induced liver injury (HILI). Historical background and the original work confirm the use of RUCAM as single term for future cases, dismissing now the term CIOMS for reasons of simplicity and clarity. RUCAM represents a structured, standardized, validated, and hepatotoxicity specific diagnostic approach that attributes scores to individual key items, providing final quantitative gradings of causality for each suspect drug/herb in a case report. Experts from Europe and the United States had previously established in consensus meetings the first criteria of RUCAM to meet the requirements of clinicians and practitioners in care for their patients with suspected DILI and HILI. RUCAM was completed by additional criteria and validated, assisting to establish the timely diagnosis with a high degree of certainty. In many countries and for more than two decades, physicians, regulatory agencies, case report authors, and pharmaceutical companies successfully applied RUCAM for suspected DILI and HILI. Their practical experience, emerging new data on DILI and HILI characteristics, and few ambiguous questions in domains such alcohol use and exclusions of non-drug causes led to the present update of RUCAM. The aim was to reduce interobserver and intraobserver variability, to provide accurately defined, objective core elements, and to simplify the handling of the items. We now present the update of the well accepted original RUCAM scale and recommend its use for clinical, regulatory, publication, and expert purposes to validly establish causality in cases of suspected DILI and HILI, facilitating a straightforward application and an internationally harmonized approach of causality assessment as a common basic tool.

Indexed as

Organ Dysfunction ScoresSeverity of Illness IndexChemical and Drug Induced Liver InjuryHumansPlant PreparationsPlant Preparationscausality assessmentCIOMSdietary supplementsdrug hepatotoxicitydrug induced liver injurydrugsherbal hepatotoxicityherb induced liver injuryherbsRUCAM

Identifiers

PMID26712744
PMCPMC4730261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.